News

Duloxetine Eases Pain of Chemo-Induced Neuropathy

Publish date: June 7, 2012

 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

CALBG 170601 was supported by the National Cancer Institute division of cancer prevention and Lilly Pharmaceuticals. Dr. Smith reported no conflicts of interest. A coauthor reported research funding from Merck. Dr. Rugo has received research funding from Genentech/Roche, Abraxis BioScience, and Bristol-Myers Squibb.

Pages

Recommended Reading

Radiofrequency Ablation Advances as Radiation Alternative in Breast Cancer
MDedge Hematology and Oncology
Usual and Worst Symptom Severity and Interference With Function in Breast Cancer Survivors
MDedge Hematology and Oncology
Breast Brachytherapy Judged Superior in Tumor Bed Control
MDedge Hematology and Oncology
Less Is Sometimes More
MDedge Hematology and Oncology
Docs Need Primer on Long-Term Effects of Chemotherapy
MDedge Hematology and Oncology
Cancer Trial Groups ECOG and ACRIN Complete Merger
MDedge Hematology and Oncology
T-DM1 Tops Capecitabine-Lapatinib in Advanced HER2-Positive Breast Cancer
MDedge Hematology and Oncology
Hodgkin's Survivors Face High Breast Cancer Risk
MDedge Hematology and Oncology
Paclitaxel Matches New Drugs as First-Line Breast Cancer Therapy
MDedge Hematology and Oncology
Cancer recurrence and survival in patients with early-stage triple-negative breast cancer
MDedge Hematology and Oncology